John M. Robertson
Expertise in
3
conditions

Dr. John M. Robertson

Radiation Oncology
3577 West 13 Mile Road, Suite Ll, 
Royal Oak, MI 
Accepting New Patients
Referral may be required
Before you request
Expertise in
3
conditions
3577 West 13 Mile Road, Suite Ll, 
Royal Oak, MI 

Overview

John Robertson is a Radiation Oncologist practicing medicine in Royal Oak, Michigan.

Dr. Robertson is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Squamous Cell Carcinoma of the Anal Canal (SCAC), Anal Cancer, Bone Tumor, and Liposarcoma.

Dr. Robertson is board certified in American Board Of Radiology. He is actively involved in clinical research, co-authoring 22 peer reviewed articles and participating in 9 clinical trials. Dr. Robertson is currently accepting new patients.

Specialties

Radiation Oncology

Licenses

Radiology in MI

Board Certifications

American Board Of Radiology

Fellowships

University of Michigan Hospitals and Health Centers

Hospital Affiliations

Corewell Health Trenton Hospital
Corewell Health Dearborn Hospital
Corewell Health Wayne Hospital
Corewell Health Beaumont Troy Hospital
Corewell Health William Beaumont University Hospital
Corewell Health Taylor Hospital
Beaumont Hospital - Dearborn
Beaumont Hospital Royal Oak

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
McLaren Health
  • HMO
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Priority Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

Rose Cancer Treatment Center
3577 West 13 Mile Road, Suite Ll, Royal Oak, MI 48073

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer
Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 24, 2026
Intervention Type: Drug, Procedure, Radiation, Other
Study Drugs: Carboplatin, Paclitaxel, FOLFOX regimen, CAPOX regimen, Docetaxel, 5FU
Study Phase: Phase 3
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Enrollment Status: Active_not_recruiting
Publish Date: August 10, 2026
Intervention Type: Procedure, Drug, Other
Study Drug: Pazopanib Hydrochloride
Study Phase: Phase 3
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate
Study Phase: Phase 3
A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma
A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Procedure, Radiation
Study Phase: Phase 3
The National Myelodysplastic Syndromes Natural History Study
The National Myelodysplastic Syndromes Natural History Study
Enrollment Status: Completed
Publish Date: February 03, 2026
Intervention Type: Other
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Enrollment Status: Completed
Publish Date: December 04, 2025
Intervention Type: Drug, Radiation, Biological
Study Phase: Phase 2
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as a Prophylaxis for Patients Receiving Chemotherapy With Intermediate Risk for Febrile Neutropenia - Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as a Prophylaxis for Patients Receiving Chemotherapy With Intermediate Risk for Febrile Neutropenia - Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
Enrollment Status: Completed
Publish Date: October 20, 2022
Intervention Type: Other
Study Phase: Not Applicable
View 8 Less Clinical Trials

22 Total Publications

Erratum to: Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 2023;117:370-377.
Erratum to: Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 2023;117:370-377.
Journal: International journal of radiation oncology, biology, physics
Published: September 25, 2024
Similar Doctors
Expertise in
41
conditions
Dr. Inga S. Grills
Radiation Oncology
Expertise in
41
conditions
Dr. Inga S. Grills
Radiation Oncology
Referral may be required
Before you request

Rose Cancer Treatment Center

3577 West 13 Mile Road, Suite Ll, 
Royal Oak, MI 
 (0.1 miles away)
248-551-5490
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Inga Grills is a Radiation Oncologist practicing medicine in Royal Oak, Michigan. Dr. Grills is highly rated in 41 conditions, according to our data. Her clinical expertise encompasses Arteriovenous Malformation, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Gamma Knife Radiosurgery. Dr. Grills is board certified in American Board Of Radiology. Dr. Grills is currently accepting new patients.

Expertise in
21
conditions
Dr. Prakash Chinnaiyan
Radiation Oncology
Expertise in
21
conditions
Dr. Prakash Chinnaiyan
Radiation Oncology
Referral may be required
Before you request

Rose Cancer Treatment Center

3577 West 13 Mile Road, Suite Ll, 
Royal Oak, MI 
 (0.1 miles away)
248-551-5490
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Prakash Chinnaiyan is a Radiation Oncologist practicing medicine in Royal Oak, Michigan. Dr. Chinnaiyan is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, Brain Tumor, and Gamma Knife Radiosurgery. Dr. Chinnaiyan is board certified in American Board Of Radiology. Dr. Chinnaiyan is currently accepting new patients.

Expertise in
23
conditions
Dr. Daniel R. Wahl
Radiation Oncology
Expertise in
23
conditions
Dr. Daniel R. Wahl
Radiation Oncology
Referral may be required

University Hospital

1500 E Medical Center Dr, Floor B2 C490, 
Ann Arbor, MI 
 (31.8 miles away)
734-936-4300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Wahl is a physician scientist at the University of Michigan specializing in cancers of the central nervous system. His research focuses on the development of new treatment strategies for brain tumors and his laboratory group is especially interested in interactions between radiation and abnormal metabolism in glioblastoma. In the clinic, he cares for a wide variety of patients with both malignant and benign tumors of the central nervous system. Dr. Wahl is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Brain Tumor, and Glioma. Dr. Wahl is currently accepting new patients.

Frequently Asked Questions about Dr. John M. Robertson

How do I make an appointment with Dr. John M. Robertson?

You can book an appointment with Dr. John M. Robertson by calling their office at 248-551-5490. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. John M. Robertson a top-rated expert for Squamous Cell Carcinoma of the Anal Canal (SCAC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. John M. Robertson is classified as an Distinguished expert for Squamous Cell Carcinoma of the Anal Canal (SCAC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. John M. Robertson specialize in?

While Dr. John M. Robertson is a Radiation Oncology, they have specific expertise in Squamous Cell Carcinoma of the Anal Canal (SCAC), Anal Cancer, and Bone Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. John M. Robertson participate in research or clinical trials?

Yes. Dr. John M. Robertson has published 22 articles and abstracts on conditions like Squamous Cell Carcinoma of the Anal Canal (SCAC). You can view a list of Dr. John M. Robertson's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. John M. Robertson accept my insurance?

Dr. John M. Robertson accepts most major insurance plans, including Blue Cross Blue Shield and Humana. We recommend calling the office directly at 248-551-5490 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Robertson's expertise for a condition
ConditionClose
    View All 89 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile